Research programme: protein kinase inhibitors - Locus/Scios
Alternative Names: Protein kinase inhibitors research programme - Locus/SciosLatest Information Update: 21 Jan 2010
At a glance
- Originator Locus Pharmaceuticals; Scios
- Class Small molecules
- Mechanism of Action Protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 14 Mar 2005 Early research in an undefined indication in the US (unspecified route)